<?xml version="1.0" encoding="UTF-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/" >

	<channel>
		<atom:link rel="self" href="http://www.drugs.com/answers/support-group/pramipexole/blog/rss/" type="application/rss+xml" />
		<atom:link rel="next" href="http://www.drugs.com/answers/support-group/pramipexole/blog/rss/?page=2" />
		<dc:creator>Drugs.com</dc:creator>
		<dc:language>en</dc:language>
		<dc:rights>Copyright 2013 Drugs.com</dc:rights>
		<link>http://www.drugs.com/answers/support-group/pramipexole/blog/</link>
		<title>Pramipexole Blog Posts - Drugs.com</title>
		<description>The latest blog posts from the Pramipexole support group brought to you by Drugs.com Answers.</description>
		<item>
			<guid isPermaLink="false">6db812399de3afc15a13018a77f70aed</guid>
			<link>http://www.drugs.com/fda/mirapex-pramipexole-safety-communication-ongoing-safety-review-possible-risk-heart-failure-13180.html</link>
			<title>Mirapex (pramipexole): Drug Safety Communication - Ongoing Safety Review, Possible Risk of Heart Failure</title>
			<description><![CDATA[
ISSUE: FDA notified healthcare profesionals about a possible increased risk of heart failure with Mirapex (pramipexole). Results of recent studies suggest a potential risk of heart failure that needs further review of available data. Because of the study limitations, FDA is not able to determine whether Mirapex increases the risk of heart failure. FDA is continuing to work with the manufacturer to clarify further the risk of heart failure with Mirapex and will update the public when more information is available.
FDA evaluated a pooled analysis of randomized clinical trials and found that heart failure was more frequent with Mirapex than with placebo; however, these results were not statistically significant. FDA also evaluated two epidemiologic studies that suggested an increased risk...
			]]></description>
			<category>Pramipexole</category>
			<pubDate>Wed, 19 Sep 2012 23:21:33 +0000</pubDate>
			<dc:creator />
		</item>
		<item>
			<guid isPermaLink="false">cc02d42b8939768b8a4f1e4d826faa79</guid>
			<link>http://www.drugs.com/news/parkinson-s-linked-behavior-problems-study-30426.html</link>
			<title>Parkinson&#039;s Drugs Linked to Behavior Problems in Study</title>
			<description><![CDATA[
TUESDAY, March 29 -- Parkinson&#039;s disease drugs called dopamine agonists appear to cause impulse control problems in almost one-quarter of patients, says a new study.
Previous research has linked dopamine agonists, which include Mirapex (pramipexole) and Requip (ropinirole), to impulse control disorders, such as gambling addiction and hypersexuality, and to compulsive behaviors, such as binge eating, overspending and excessive computer use.
In this study, Mayo Clinic researchers analyzed Parkinson&#039;s disease patient records over two years.
&#34;What we found was that as many as 22 percent of patients during that two-year period had a new-onset impulse control disorder,&#34; lead investigator and neurology fellow Dr. Anhar Hassan said in a Mayo Clinic news release.
The higher...
			]]></description>
			<category>Pramipexole</category>
			<pubDate>Wed, 30 Mar 2011 21:54:48 +0000</pubDate>
			<dc:creator />
		</item>
		<item>
			<guid isPermaLink="false">0fcee95cc7b4f2067da8ba1e330de18e</guid>
			<link>http://www.drugs.com/news/parkinson-s-tied-compulsive-behaviors-24349.html</link>
			<title>Parkinson&#039;s Drugs Tied to Compulsive Behaviors</title>
			<description><![CDATA[
MONDAY, May 10 -- Medicines used to treat Parkinson&#039;s disease may increase the risk of impulse control disorders, such as problem gambling, compulsive shopping and binge eating, researchers warn.
In a new study that included 3,090 patients being treated for Parkinson&#039;s at 46 movement disorder centers in the United States and Canada, the researchers found that 13.6 percent of the patients had impulse control disorders. These impulse disorders included gambling (5 percent), compulsive sexual behavior (3.5 percent), compulsive shopping (5.7 percent) and binge eating (4.3 percent), and nearly 4 percent of the patients had two or more of these disorders.
Impulse control disorders were more common among patients taking dopamine agonist medications (17.1 percent) than in those not...
			]]></description>
			<category>Pramipexole</category>
			<pubDate>Mon, 10 May 2010 18:37:14 +0000</pubDate>
			<dc:creator />
		</item>
		<item>
			<guid isPermaLink="false">1dc3a89d0d440ba31729b0ba74b93a33</guid>
			<link>http://www.drugs.com/news/cutting-parkinson-s-linked-effects-22013.html</link>
			<title>Cutting Parkinson&#039;s Drug Dose Linked to Withdrawal Effects</title>
			<description><![CDATA[
WEDNESDAY, Jan. 13 -- Reduced dosages of dopamine agonists, drugs routinely used to treat Parkinson&#039;s disease, can cause symptoms similar to those experienced by addicts in withdrawal, such as anxiety, panic attacks, pain, dizziness and drug cravings, researchers say.
The symptoms of what the researchers have dubbed &#34;dopamine agonist withdrawal syndrome&#34; have been linked to a disruption in levels of dopamine in the brain, according to the study published in the Jan. 12 issue of the Archives of Neurology.
&#34;Like cocaine and methamphetamines, dopamine agonists work by stimulating the reward pathways in the brain,&#34; senior study author Dr. Melissa J. Nirenberg, said in a news release from Weill Cornell Medical Center.
&#34;For this reason, it makes sense that they would...
			]]></description>
			<category>Pramipexole</category>
			<pubDate>Thu, 14 Jan 2010 17:01:01 +0000</pubDate>
			<dc:creator />
		</item>
	</channel>
</rss>